GMR
The Original

CLINICOPATHOLOGICAL CORRELATION IN CHRONIC KIDNEY DISEASE: A MULTIDISCIPLINARY REVIEW

Dr. P. Balaji[1], Dr. P. Shanmugasundaram[2], Shivangi Gupta[3], Dr. Sunil Pathak[4], Dr. Ritesh Kumar[5]

[1]Professor, Department of Pharmacology, School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advanced Studies (Vistas), Pallavaram, Chennai - 600 117, ORCID: 0000-0001-5317-1661
[2]School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advanced Studies (Vistas), Pallavaram, Chennai - 600 117, ORCID: 0000-0003-2961-0665 Email Id: dean.sps@vistas.ac.in
[3]PhD scholar, Medical Microbiology, Teerthanker Mahaveer Medical College and Research Centre, Bagadpur, Moradabad, Uttar Pradesh- 244001, ORCID: 0009-0006-6628-4592 Email ID: shivangigupta3999@gmail.com
[4]Professor, Department of Pediatrics, Dr. N. D. Desai faculty of Medical Science and Research, Dharmsinh Desai University, Nadiad, ORCID: https://orcid.org/0000-0001-8777-3249, Email ID: drsunilpathak@yahoo.co.in
[5]Assistant Professor, Yogic Science School of Arts & Humanities, Maya Devi University, Dehradun, ORCID: https://orcid.org/0000-0001-8378-4709, Email: dr.ritesh.rke@gmail.com

ABSTRACT

Chronic kidney disease (CKD) is a heterogeneous, progressive condition where the measurement of functional aspects and clinical phenotypes might not be sufficient in evaluating the underlying structural damage. This review synthesizes evidence on clinicopathological correlation in CKD and evaluates how integrating histopathology with clinical assessment, laboratory markers, and imaging improves diagnostic precision and prognostic assessment. Key clinicopathological relationships are highlighted, including how proteinuria and active urinary sediment often signal glomerular injury, whereas declining renal function frequently aligns with the burden of tubulointerstitial fibrosis and vascular disease. The review also examines how pathological severity generally increases with advancing CKD stage, limiting reversibility and narrowing therapeutic windows. Importantly, discordance between presumed clinical diagnoses and biopsy findings is common in systemic and comorbidity-driven CKD, underscoring the value of tissue-based evaluation in selected cases. A multidisciplinary framework involving nephrology, pathology, radiology, and laboratory medicine is emphasized as essential for integrated interpretation and individualized care. Emerging biomarkers, advanced imaging approaches, and risk prediction models are discussed as tools that may enhance stratification and support personalized management, while ongoing challenges include disease heterogeneity, methodological limitations, and delayed recognition of progressive injury. Clinicopathological integration provides a robust pathway toward more accurate classification, targeted intervention, and improved outcomes in CKD.

KEYWORD: chronic kidney disease, renal biopsy, clinicopathological correlation, risk stratification, multidisciplinary care

1. INTRODUCTION

Chronic kidney disease CKD is a chronic disease that is marked by structural or pathological changes in the kidney structure or functionality, with severe repercussions in terms of patient survival and quality of life. It is characterized by a gradual diminishing in the decreasing in estimated glomerular filtration rate (eGFR) and/or damage signs in the kidneys, which can often be silent till too late. This vicious cycle is a contributor to the slow diagnosis and absence of early treatment that has led to CKD becoming a major burden to clinicians across the entire globe [1]. The biological process underlying renal injury and repair is a complicated one, and this has been reflected in the extensive etiology and pathology of this disease. The CKD prevalence has increased tremendously across the globe within the past two decades as a result of the rising prevalence of diabetes mellitus, hypertension, obesity, and ageing of the population. These trends have made CKD an important component of the non-communicable disease burden in the globe, and the clinical and economic implications associated with it have been of a severe nature [2]. Not only does CKD put a person at risk of end-stage kidney disease that needs dialysis or transplantation, but it also has a significant effect on cardiovascular risk, which adds to its overall mortality outcome. In terms of public health, CKD is an increasing and disparate burden. The prevalence, access to care, and outcomes have shown significant regional differences with the highest prevalence and lowest prevalence in high-income and low- and middle-income countries, specific to epidemiological studies [3].

The Global Burden of Disease Study has also conducted comprehensive analyses to indicate that CKD is one of the most dominant causes of years of life lost and disability-adjusted life years in the world, hence the need to consider it a priority among health systems and health policy-makers [4]. In spite of this awareness, CKD is not well diagnosed and treated in most environments. Functional parameters of CKD clinical assessment are based on estimated glomerular filtration rate, proteinuria, and imaging. Nevertheless, these tests are not always sufficient to identify the structural impairment that underlies them or to differentiate between different pathological mechanisms that have overlapping clinical manifestations. Clinicopathological correlation fills this gap through a combination of clinical information and renal

histopathology and thus increases the accuracy of diagnosis. Investigations conducted on the basis of the renal biopsy findings revealed that such clinical syndromes as proteinuria or progressive renal failure each has different prognostic and therapeutic consequences and might be produced by different histological lesions [5]. The significance of clinicopathological correlation is even greater in severe CKD, in which irreversible damage could obscure the disease process initially. Clinico-pathological studies in hemodialysis patients have shown that there is a significant discrepancy between clinical diagnosis and biopsy results, and this has highlighted the shortcomings of clinical diagnosis relying on clinical examination alone [6]. This is what makes such observations relevant towards a more integrated approach to the evaluation of CKD.

Since CKD is heterogeneous and its clinical course is multifaceted, a multidisciplinary approach, including nephrologists, pathologists, radiologists, and laboratory professionals, is needed. The aim of this review is to summarize the available literature on clinicopathological correlations in CKD, the mutual benefits of working on the interdisciplinary level, and the role of integrated clinical and pathological data in understanding the disease, its prognosis, and managing it on a case-by-case basis.

2. REVIEW METHODOLOGY

The review is a synthesis of the available evidence on clinicopathological correlation in chronic kidney disease by conducting a systematic review of the available literature. Peer-reviewed articles that featured clinical assessment, renal pathology, disease progression, and multidisciplinary evaluation in CKD were taken into consideration. As much as possible, studies that investigated the association of clinical appearance, histopathological observations, and prognostic or therapeutic significance were emphasized. The reviewed literature has been assessed on a qualitative basis and organized into themes to come up with a coherent and sufficient overview. The purpose of this approach was to draw out major ideas, have patterns emerge and put the present issues concerning the assessment and management of chronic kidney disease in perspective.

3. Overview of Chronic Kidney Disease

Chronic kidney disease (CKD) is a condition of having systemic or structural flaws of the kidneys or defects that have existed for at least three months and have implications for the health outcomes. These abnormalities may be either in the form of a reduced estimated glomerular filtration rate (eGFR), which is a sign of kidney damage (such as albuminuria) or structural change, which is detected on imaging or histopathology [7]. This would be the general definition suggesting the heterogeneity of CKD, which encompasses a variety of disease processes that are different in their etiology, severity, and clinical progression. The present approach to CKD is a multiple system disorder, which has systemic effects, and not a renal disorder [8]. The international recommendations indicate that the estimation of GFR and the presence of albuminuria largely determine the classification and staging of CKD. According to eGFR, CKD is divided into five stages, with mild functional impairment to end-stage kidney disease and albuminuria is divided into three levels where the deficiencies of protein excretion in the urine are increasing. The system is an integrated staging system that provides a platform of risk stratification, prognostication and clinical decision-making. The statistics are population-based and indicate that the initial stages of CKD are far more prevalent than the severe disease, yet they are often undetected since they do not manifest, and the overt symptoms take place [9].

The etiology of CKD is a complex process that varies according to populations. Diabetes mellitus and hypertension are the most prevalent conditions in developed and developing countries and constitute the major part of the cases in the world [10]. Others are glomerulonephritis, hereditary kidney disorders, chronic interstitial nephritis, and systemic kidney diseases. Besides the primary etiologies, there are various risk factors that lead to the development and progression of CKD, such as old age, genetic predisposition, obesity, cardiovascular disease, and exposure to nephrotoxic agents [8]. The burden of diseases among vulnerable populations is also enhanced by socioeconomic factors and inadequate access to health care.

The course of CKD is progressive, but the progression of the disease in relation to the deterioration of the kidney functions differs significantly in different people. The development of the disease is caused by the complex interplay of changes in the hemodynamics, metabolic derangements, and maladaptive cellular responses in the kidney [11]. The major pathological mechanisms include glomerulosclerosis, tubulointerstitial fibrosis, and vascular damage that slowly decrease the functional nephron mass, resulting in the irreversible loss of renal functioning. Notably, the course is not linear, and a patient might have a long stability, or he or she may become progressively worse. The inflammation has developed into a key process that determines the progression and outcomes of CKD. Sustained low-grade inflammations are associated with structural damage and fibrosis and enhance the rate of renal failure, as well as associate CKD with systemic complications like cardiovascular disease and mortality [12]. With the deterioration of kidney functioning, patients become more vulnerable to end-stage kidney disease, cardiovascular events, and early death. It is, hence, necessary to understand the definition and classification, etiological diversity and progression of CKD to place clinicopathological correlations into perspective and enhance prevention, early and long-term management. Chronic kidney disease has been currently classified incorporating the categories of eGFR and albuminuria to stratify the severity of the disease and prognostic risk (Table 1).

Table 1. Classification and Staging of Chronic Kidney Disease

Parameter	Category	Criteria	Clinical significance
eGFR	G1–G2	≥60 mL/min/1.73 m²	Early CKD is often asymptomatic
	G3a–G3b	30–59 mL/min/1.73 m²	Moderate CKD, rising complications

	G4	15–29 mL/min/1.73 m²	Severe CKD, high progression risk
	G5	<15 mL/min/1.73 m²	Kidney failure
Albuminuria	A1–A3	<30 to >300 mg/g	Risk stratification and prognosis

4. Clinical Evaluation of Chronic Kidney Disease

4.1 Clinical Manifestations and Comorbidities

The clinical assessment of chronic kidney disease (CKD) aims at tackling the acquisition of the disease at an early stage, examination of the disease severity, and detection of related conditions that affect the progression and outcomes. At an earlier stage, CKD may be asymptomatic, and the nonspecific signs of the disease include fatigue, lack of appetite, nocturia, and mild edema only, with a decrease in renal activity. The disease is therefore often incidentally found during routine health assessments or even during investigations into other, more unrelated ailments [13]. With further progression of CKD, the patients can acquire apparent complications such as uremic symptoms, anemia, electrolyte imbalances, metabolic acidosis, and fluid overload. The clinical picture of CKD is based on comorbidities, which significantly alter its course. The most frequent comorbid conditions are diabetes mellitus and hypertension, which are the most prevalent causes of CKD in the world. Their co-occurring condition quickens renal dysfunction and significantly elevates cardiovascular illness and death rates [14]. Other comorbidities that are commonly encountered are cardiovascular disease, dyslipidemia, obesity, and chronic inflammatory disorders. Holistic assessment of the renal and systemic health is thus necessary to conduct a comprehensive clinical evaluation.

4.2 Laboratory Biomarkers and Functional Assessment

Diagnosis and monitoring of CKD are based on laboratory studies. The most common measure of kidney functionality is still the estimated glomerular filtration rate, which can be calculated with the help of serum creatinine-based formulas, whereas albuminuria and proteinuria are the indicators of structural damage to the kidney and the predictors of disease progression [13]. Other lab parameters, such as hemoglobin, serum electrolytes, bicarbonate, calcium, phosphate, and parathyroid hormone levels, are regularly determined to determine complications and manage them. In addition to traditional tests, novel biomarkers, which indicate certain pathophysiological events, including tubular damage, inflammation, and fibrosis, are gaining more and more interest. Such biomarkers have shown the potential in enhancing the early detection, risk stratification and prognostication in chronic kidney disease. Nevertheless, their application in clinical practice is currently not widespread, as the research has positive results, yet there are concerns with their standardization, accessibility, and affordability [15].

4.3 Imaging Techniques in CKD Evaluation

Imaging examinations are necessary to facilitate structural information complementing clinical and laboratory evaluation. Renal ultrasonography is the most frequently utilized modality, which provides an assessment of the renal size, cortical thickness, echogenicity, and obstruction or intrinsic anomalies. Imaging is also involved in the evaluation of extra-renal complications, especially in chronic kidney disease-mineral and bone disorders, in which vascular calcification and skeletal loss are some of the factors involved in poor outcomes [16]. The new technological developments have increased the imaging role in the assessment of CKD. New ultrasound-based methods are elastography and contrast-enhanced ultrasound, can be used to evaluate renal perfusion, tissue stiffness, and fibrotic changes noninvasively. Such methods have the potential of identifying early structural changes before serious functional deterioration develops to be easily noticed, which may lessen the need to resort to invasive diagnostic methods [17].

Clinical evaluation of CKD should be conducted with the implementation of laboratory biomarkers and imaging outcomes, along with assessment of clinical manifestations and comorbidities. It is the basis of correct diagnosis, staging, and follow-up, and a vital device of the critical framework of meaningful clinicopathological correlation and individualized management of patients. Chronic kidney disease should be evaluated clinically by using a systematic approach to the evaluation of symptoms, comorbidities, functional markers, and changes in structure (Table 2). The combination of these clinical, laboratory and imaging contributions with renal histopathology is depicted in Figure 1.

Table 2. Clinical Evaluation of Chronic Kidney Disease

Domain	Key components	Assessment tools	Clinical relevance
Clinical features	Edema, fatigue, uremic symptoms	History, examination	Disease severity
Comorbidities	Diabetes, hypertension, CVD	Clinical records	Progression risk
Kidney function	eGFR trends	Serum creatinine-based equations	Staging, monitoring
Kidney damage	Proteinuria, hematuria	ACR/PCR, urine microscopy	Etiological clues
Imaging	Size, echogenicity	Ultrasound ± advanced imaging	Chronicity, obstruction



Figure 1. Integrated Clinicopathological Framework in CKD

5. Pathological Basis of Chronic Kidney Disease

5.1 Indications and Role of Renal Biopsy

The pathogenesis of chronic kidney disease (CKD) is a reflection of a progression of cellular damage, maladaptive repair, and scarring that eventually decreases the functional nephron mass and allows chronicity to prevail [18]. On a mechanistic basis, the interacting pathways that maintain CKD progression are tubular epithelial responses to stress, sustained interstitial inflammation, microvascular rarefaction, and fibrogenic signaling, all of which lead to irreversible structural remodeling [19]. Although clinical parameters are measures of functional loss, they are frequently unable to characterize the pre-eminent lesion type or differentiate between separate disease processes that have an overlapping phenotype. In that regard, renal biopsy is by all means the most direct mechanism of making etiological diagnosis, activity/chronicity grading and finding potentially curable processes in the selected CKD presentations [20]. Renal biopsy is most often taken into consideration when the clinical picture is not explained with the help of noninvasive assessment, e.g., unexplained proteinuria, atypical or rapidly progressive deterioration of kidney functions, possible glomerular disease, or systemic conditions with renal involvement, because the histology is capable of narrowing down the diagnosis and the choice of the treatment in comparison with the clinical inference. Notably, the interpretation of biopsy also helps to improve risk stratification, by recording the burden of irreversible injury (e.g., sclerosis and fibrosis) versus the potentially reversible inflammatory activity [20, 21].

5.2 Histopathological Components of Chronic Kidney Disease

The three key compartments that are assessed through histopathology in CKD include glomeruli, tubulointerstitium and vessels. The glomerular lesions can be mesangial expansion, segmental or global sclerosis, capillary wall alterations, and podocyte damage, which all interfere with filtration and add to proteinuria. Tubulointerstitial processes, especially tubular atrophy and interstitial fibrosis, frequently have a strong correlation with deteriorating renal function and constitute a final common pathway across a wide range of CKD etiologies. Parenchymal injury may be further exacerbated by vascular defects like arteriosclerosis and arteriolar hyalinosis, which decrease perfusion, favor chronic ischemia, and increase fibrotic remodeling, thus accelerating functional loss [18, 19]. Figure 2 summarizes the key histopathological compartments in CKD and their integration towards fibrosis, loss of nephrons and disease progression.



Figure 2. Histopathological Components and Progression in CKD

5.3 Common Pathological Patterns in Chronic Kidney Disease

In CKD, renal histology usually transforms into less active inflammatory or proliferative lesions in more chronic, fibrotic, and sclerotic forms across the stages of CKD. There is evidence that histology has evaluated the relative importance of irreversible lesions, which has been increasing with disease stage, restricting the extent of reversibility and decreasing therapeutic opportunities [22]. Since the chronic lesions may prevail in the late disease, early biopsy, where clinically may be more informative about etiology and treatment planning. Independent prognostic variables are also the histopathological variables. Retrospective cohort data have shown that the degree of interstitial fibrosis and tubular atrophy, among other characteristics of chronicity, are predictive of kidney failure progression beyond that accounted by clinical measures alone at baseline [23]. Pathological assessment in nonfunctioning or badly injured kidneys can also determine epithelial remodeling and, in a limited number of settings, neoplastic transformation, which points to the scope of pathology that can be linked to chronic kidney damage [24].

6. Clinicopathological Correlation in Chronic Kidney Disease

6.1 Correlation of Clinical Parameters with Histopathological Findings

Clinicopathological correlation has been the key to the heterogeneity of chronic kidney disease (CKD) because clinical signs do not always reflect the structural damage. A better definition of the disease and a more precise diagnosis through correlation of clinical parameters (proteinuria, eGFR, renal function decline rate) and histopathological data can be achieved. The research has revealed that clinical manifestations resembling each other in various clinical environments can be associated with various pathological entities, highlighting the weaknesses of clinical evaluation by itself [25]. Proteinuria is typically linked with glomerular disease, such as podocyte damage and glomerulosclerosis, whereas decreased renal functioning is a likely indicator of the accumulation of tubulointerstitial fibrosis and vascular injury. Clinicopathological studies in the populations have shown that interstitial and vascular lesions are often more strongly related to renal dysfunction as compared with isolated glomerular alterations, and thus, such comprehensive histological analysis is of prognostic importance [26].

6.2 Relationship Between CKD Stage and Pathological Severity

There is a stable correlation between the stage of CKD and the severity of pathological lesions. Over time, chronic, irreversible alterations (global glomerulosclerosis, tubular atrophy, interstitial fibrosis, and vascular sclerosis) are gradually increased as the kidney disease advances. The initial phases of CKD can still be characterized by active or mixed lesions, which have a possible therapeutic value, but after the extreme stages, the process is usually characterized by the presence of chronic scarring, which restricts reversibility and response to treatment [26]. This pathological process is similar to functional deterioration and emphasizes the need to clinically assess the pathology on time. The knowledge of the increase in the severity of pathology with CKD stage can help clinicians carry out the prognostication, therapeutic planning, and define the possible usefulness of diagnostic methods, including renal biopsy.

6.3 Concordance and Discordance Between Clinical and Biopsy Diagnoses

Clinical diagnosis and histopathological results show variable concordance in CKD, and severe discordance has been reported in numerous studies. In patients with comorbid systemic diseases, renal biopsy frequently has different diagnoses than the first clinical impression, especially in patients. Indeed, non-diabetic renal diseases have been identified in biopsy studies and have altered their place in management and prognosis in diabetic patients with high frequency [27]. Likewise, systemic inflammatory diseases, including rheumatoid arthritis, can also cause a large array of renal pathologies that cannot be predicted by clinical features alone. Such settings have found that clinicopathological correlation is useful in identifying unanticipated lesions and elucidating the mechanism of disease [28]. These results support the fact that

clinicopathological correlation is not a confirmatory one but may be a transformative factor in the process of providing personalized care. Table 3 identifies the major associations between common clinical phenotypes and underlying histopathological equivalents as well as their interpretative value.

Table 3. Clinicopathological Correlation in CKD

Clinical finding	Histopathological correlate	Interpretative value	Management implication
Heavy proteinuria	Podocyte injury, glomerulosclerosis	Glomerular pathology	Consider biopsy
Declining eGFR	Tubulointerstitial fibrosis	Chronicity assessment	Prognosis
Active urine sediment	Inflammatory lesions	Disease activity	Targeted therapy
Small kidneys	Global sclerosis	Irreversibility	Conservative planning
Systemic disease	Mixed or unexpected lesions	Diagnostic discordance	Management revision

7. Multidisciplinary Perspectives in CKD Assessment

7.1 Contributions of Different Disciplines

Chronic kidney disease (CKD) is a disease that involves concerted efforts of different medical disciplines since it is a systemic disease, and it manifests itself in many ways. The provision of clinical paradigms of diagnosis, staging and longitudinal management is the responsibility of nephrology, but useful data are provided by pathology, such as the histological evaluation of renal tissue that is useful in detecting lesions with prognostic effects on functional indicators. These findings suggest further systemic values of renal pathology and prove the fact that a combination of the results of biopsy should be encouraged in clinical practice [29]. The role of radiology is complementary because it provides a noninvasive assessment of the structure of the kidney and its functionality. Imaging modalities are useful in the evaluation of kidney size, parenchymal integrity, perfusion and chronicity, especially where biopsy is contraindicated or to monitor disease progression [30]. Laboratory medicine also helps in multidisciplinary assessment by offering kidney biomarkers of injury, kidney functionality, and systemic involvement, making it easy to detect and monitor CKD and its complications early [31].

7.2 Integrated Diagnostic and Interpretative Approaches

The main focus of the accurate interpretation of CKD is the integrated approach to diagnostics, primarily in patients with complex comorbidities or unusual disease progression. The relation of clinical data to pathological, laboratory, and imaging evidence will enable a more accurate distinction between active, possibly reversible, and the unreversible chronic damage. The application of advanced imaging, e.g. multiparametric magnetic resonance imaging, has been proven to be useful in supplementing laboratory parameters in order to make a prognostic judgment, where other noninvasive systems are being provided to guarantee that disease evaluation is refined [32]. This type of integration is particularly applicable to systemic metabolic disorders, as well as multisystem disorders, in which the renal pathology can be either insidious or indirect. Multidisciplinary interpretation reduces the ambiguity in the diagnosis process, in addition to improving the risk assessment process by providing the opportunity to contextualize the renal results in the entire clinical picture. Figure 3 depicts a multidisciplinary route of connecting clinical course, laboratory, imaging, and specific biopsy consideration in the support of risk stratification and customized care.



Figure 3. Multidisciplinary Decision Pathway in CKD Management

7.3 Clinical Value of Multidisciplinary Collaboration

Multidisciplinary teamwork has a practical clinical importance in enhancing diagnostic quality, prognostication, and individual management interventions in CKD. Joint assessment allows making wise decisions on the suitability of invasive diagnostics, therapeutic treatment and imaging research. Guidance on the use of contrast-enhanced imaging in patients

with kidney disease is done by consensus, which highlights the need to balance diagnostic value versus the possible risk of kidney disease, and this is through the joint clinical judgment [33].

A combination of nephrology, pathology, radiology, and laboratory medicine strengthens clinicopathological interpretation and aids in the provision of personalized and patient-centered care. Multidisciplinary assessment is an essential part of quality clinical care and long-term treatment and management in CKD, where the disease progression and outcomes are unevenly distributed. Table 4 summarizes the complementary roles of nephrology, pathology, radiology, and laboratory medicine in the integrated assessment of CKD.

Table 4. Multidisciplinary Approach to CKD Assessment

Discipline	Primary role	Key contribution	Added value
Nephrology	Clinical management	Phenotyping, staging	Longitudinal care
Pathology	Tissue diagnosis	Lesion characterization	Etiology, prognosis
Radiology	Structural assessment	Noninvasive imaging	Chronicity evaluation
Laboratory medicine	Biomarker analysis	Functional monitoring	Early detection
Multidisciplinary team	Integrated interpretation	Unified assessment	Personalized care

8. Prognostic and Therapeutic Implications

8.1 Pathological Predictors of Disease Progression

The prognostication of chronic kidney disease (CKD) requires the identification of factors influencing the course of renal decline, such as the risk of accelerated decline and unfavorable outcomes. The progression is not linear among patients; the CKD has non-homogeneous patterns determined by the severity of the underlying disease, comorbidity and continuous harmful exposures. Narrative syntheses have highlighted that progression may be neither linear nor determined by assessable and risk factors that cannot be assessed, and that structured prognostic assessment is critical to intervene and plan on time [34]. Patients with the highest risk have a tendency to decline over time, and early recognition of such patterns has direct effects on follow-up intensity and treatment goals. Prognostic assessment has also been furthered by the use of dynamic risk prediction models to incorporate the changing clinical variables to allow an estimate to be made that can respond to changes in kidney functioning and risk profile. The dynamic approach of CKD progression with a well-described description could demonstrate the ability of repeated measures to enhance prediction when using three years of baseline data, which is utilized for predicting risk of clinically significant outcomes over time when compared to a static baseline data, even though both methods could significantly predict outcomes [35]. Notably, cohorts of rapid linear deterioration have emphasized that rapid deterioration is not only linked to the increased risk of kidney failure but also the increased mortality, which confirms the importance to analyze renal curves as indicators of the general systemic vulnerability [36].

8.2 Impact of Clinicopathological Correlation on Management Strategies

Clinicopathological correlation enhances the management as it associates clinical pathways as seen with disease pathways and probable responsiveness to treatment. Clinical indicators of progress, including the increase in albuminuria, the reduction in estimated glomerular filtration rate and the lack of metabolic control, have been repeatedly shown to be predictors of more aggressive deterioration in diabetic kidney disease, and used to intensify therapy and trigger risk-based referral earlier [37]. Interpretation of clinical trends in combination with structural or disease-specific context can enable clinicians to better differentiate between patients who are likely to respond to aggressive risk-factor modification and those patients whose progression is the manifestation of irreversible severe damage. On a systems level, there has been evidence that supports predictive approaches, and this has promoted the use of tools of risk in a structured manner to inform the timing of education in kidney replacement therapy, frequency of surveillance, and prioritization of multidisciplinary interventions. This is especially applicable in determining the course of escalation, the optimal approaches to blood pressure and proteinuria management, or the future courses of renal replacement therapy, depending on future risk projections.

8.3 Role in Risk Stratification and Personalized Care

Risk stratification would allow the personalization of CKD care to match the intensity of monitoring and intervention with the predicted trajectory of the patient. The analysis of prediction models has demonstrated a large range of inputs, predicted outcomes, and clinical utility of the models under review, and it is important to note that when choosing validated tools, it is necessary to consider the purpose at which the decision must be taken (e.g., at risk of kidney failure, fast progression, or death) [38]. As studies in predictive modelling show, the integration of routinely available clinical variables into formulaic risk equations can be used to aid individualized prognostic estimates and lessen the use of subjective judgment [39].

9. Challenges and Future Direction

Although significant progress has been achieved in the study and treatment of chronic kidney disease (CKD), significant constraints remain in the evidence base and the assessment and management of CKD within normal practice. One of the main obstacles is the heterogeneity of CKD; patients vary in many aspects in terms of etiology, comorbidity burden, and rate of progression, but most of the studies use general category sets that can conceal clinically relevant subsets. This leads to differences in reported relationships, reduces the ability to generalize in different populations, and makes it difficult to translate evidence into universal patterns of practice [40]. Reliance on creatinine-based approximations of kidney

functioning can also result in methodological limitations because of its ability to be impacted by muscle mass, diet and acute illness, which could misclassify stage and risk in a real-world context [40].

The restriction is especially high in the advanced CKD when comorbidities, polypharmacy and competing risks often complicate not only the clinical management but also the outcome research. Trials in patients with late-stage disease are usually underrepresented, and observational studies might also be biased in selection and incomplete capture of confounding variables of interest. These gaps minimize the trust in the use of evidence in a consistent manner, particularly in the process of weighing the management of the symptoms, cardiovascular risks, and preparation for kidney replacement therapy. Also, the lack of consistency in the definition of outcome (e.g., variable endpoints of progression), and variability in the follow-up period and the lack of integrated histopathology or longitudinal structural evaluation limit the strength of the clinicopathological inference in most settings [41].

The future directions in CKD focus on the enhancement of early diagnosis, further development of risk stratification, and more person-centered care with the development of new diagnostic instruments. Complementary focus on biomarker sets outside of traditional markers such as serum creatinine and albuminuria that define specific biological occurrences, such as inflammation, tubular damage, and fibrosis, is increasing. Such tools may improve the resolution of prognostic, distinguish between active injury and chronic scarring and identify high-risk patients earlier in the illness. This will improve the clinical usefulness of clinicopathological correlation. However, this should be subjected to practice via experiments, which are strictly validated in other populations, by assay standardization as well as demonstrating incremental benefit over traditional clinical models. At the same time, the multidisciplinary model and innovations in care delivery are deemed to be essential in the process of complex and advanced CKD treatment. In the future, biomarker-based risk prediction and care pathways organized, improved interaction with a patient, and improved disease coordination planning are likely to be integrated. The critical issues that have existed long before the advanced CKD, such as slow referral, fragmented care, and a high symptom burden, will need to be solved to improve the outcomes and make the treatment choices more aligned with the patient-centered goals.

10. CONCLUSION

Chronic kidney disease is a complex heterogeneous disorder, in which the clinical expression and functional impairment rarely play a role in the degree of structural injury. This review brings out the urgency of the need of clinicopathological correlation to fill this gap, and how clinical parameters in conjunction with histopathological findings can enhance the accuracy of diagnosis, elucidate the pathophysiology of disease and enhance prognostic analysis. Renal pathology provides a basic apprehension of the activity, chronicity and reversibility of damage to the kidney, which in addition enables therapeutic choices to be made with enhanced cognizance of what is required and what is not required and unhelpful. The successful realization of comprehensive CKD assessment is concerned with the creation of a multidisciplinary decision-making model (to involve nephrology, pathology, radiology, and laboratory medicine). Such collaboration facilitates the concerted interpretation of functional, structural and molecular data and results in the risk stratification and individual management along the CKD continuum. Despite the positive perspectives regarding the creation of predictive models and novel diagnostic solutions, it is not yet possible to disclose the challenges linked to the individuality of diseases, the methodological issues, and the delay in the progressive injury recognition. To address these shortcomings, there will be a need to address them through standardized multidisciplinary models and translational research to improve the results. Lastly, a substantial clinicopathological integration offers a platform for more precise patient-centered treatment in chronic kidney disease.

REFERENCES

1. Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. The lancet. 2017 Mar 25;389(10075):1238-52.
2. Kalantar-Zadeh K, Jafar TH, Nitsch D, Neuen BL, Perkovic V. Chronic kidney disease. The lancet. 2021 Aug 28;398(10302):786-802.
3. Cockwell P, Fisher LA. The global burden of chronic kidney disease. The lancet. 2020 Feb 29;395(10225):662-4.
4. Bikbov B, Purcell CA, Levey AS, Smith M, Abdoli A, Abebe M, Adebayo OM, Afarideh M, Agarwal SK, Agudelo-Botero M, Ahmadian E. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The lancet. 2020 Feb 29;395(10225):709-33.
5. Ismail MI, Lakouz K, Abdelbary E. Clinicopathological correlations of renal pathology: A single center experience. Saudi Journal of Kidney Diseases and Transplantation. 2016 May 1;27(3):557-62.
6. Shruthi HY, Kumar MP, Roopashree G. Clinico-pathological correlation study in chronic kidney disease patients undergoing hemodialysis. Indian J Pathol Oncol. 2023 Jun 17;17:141-7.
7. Romagnani P, Remuzzi G, Glassock R, Levin A, Jager KJ, Tonelli M, Massy Z, Wanner C, Anders HJ. Chronic kidney disease. Nature reviews Disease primers. 2017 Nov 23;3(1):1-24.
8. Ammirati AL. Chronic kidney disease. Revista da Associação Médica Brasileira. 2020 Jan 13;66:s03-9.
9. Centers for Disease Control and Prevention. Chronic kidney disease in the United States, 2019. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention. 2019 Mar;3.
10. Lv JC, Zhang LX. Prevalence and disease burden of chronic kidney disease. Renal fibrosis: mechanisms and therapies. 2019 Aug 9:3-15.
11. Zhong J, Yang HC, Fogo AB. A perspective on chronic kidney disease progression. American Journal of Physiology-Renal Physiology. 2017 Mar 1;312(3):F375-84.

12. Mihai S, Codrici E, Popescu ID, Enciu AM, Albulescu L, Necula LG, Mambet C, Anton G, Tanase C. Inflammation-related mechanisms in chronic kidney disease prediction, progression, and outcome. Journal of immunology research. 2018;2018(1):2180373.
13. Gaitonde DY, Cook DL, Rivera IM. Chronic kidney disease: detection and evaluation. American family physician. 2017 Dec 15;96(12):776-83.
14. Gómez JC, Lorido JA. Clinical assessment and treatment of diabetes in patients with chronic kidney disease. Revista Clínica Española (English Edition). 2018 Aug 1;218(6):305-15.
15. Zhang WR, Parikh CR. Biomarkers of acute and chronic kidney disease. Annual review of physiology. 2019 Feb 10;81(1):309-33.
16. Pimentel A, Bover J, Elder G, Cohen-Solal M, Ureña-Torres PA. The use of imaging techniques in chronic kidney disease-mineral and bone disorders (CKD-MBD)—A systematic review. Diagnostics. 2021 Apr 26;11(5):772.
17. Fleig S, Magnuska ZA, Koczera P, Salewski J, Djudjaj S, Schmitz G, Kiessling F. Advanced ultrasound methods to improve chronic kidney disease diagnosis. npj Imaging. 2024 Jul 25;2(1):22.
18. Agarwal A, Nath KA. Pathophysiology of chronic kidney disease progression: organ and cellular considerations. InChronic renal disease 2020 Jan 1 (pp. 263-278). Academic Press.
19. Ren J, Dai C. Pathophysiology of chronic kidney disease. InChronic Kidney Disease: Diagnosis and Treatment 2019 Nov 9 (pp. 13-32). Singapore: Springer Singapore.
20. Schnuelle P. Renal biopsy for diagnosis in kidney disease: indication, technique, and safety. Journal of clinical medicine. 2023 Oct 9;12(19):6424.
21. Bandari J, Fuller TW, Turner RM, D'Agostino LA. Renal biopsy for medical renal disease: indications and contraindications. Can J Urol. 2016 Feb 1;23(1):8121-6.
22. Trevisani F, Di Marco F, Capitanio U, Dell'Antonio G, Cinque A, Larcher A, Lucianò R, Bettiga A, Vago R, Briganti A, Salonia A. Renal histology across the stages of chronic kidney disease. Journal of Nephrology. 2021 Jun;34(3):699-707.
23. Eadon MT, Schwantes-An TH, Phillips CL, Roberts AR, Greene CV, Hallab A, Hart KJ, Lipp SN, Perez-Ledezma C, Omar KO, Kelly KJ. Kidney histopathology and prediction of kidney failure: a retrospective cohort study. American Journal of Kidney Diseases. 2020 Sep 1;76(3):350-60.
24. Lin X, Goyal R, Yang XJ. Pathologic characterization of renal epithelial neoplasms arising in nonfunctioning kidneys. Human pathology. 2020 Mar 1;97:1-7.
25. Diana NE, Davies M, Mosiane P, Vermeulen A, Naicker S. Clinicopathological correlation of kidney disease in HIV infection pre-and post-ART rollout. PLoS One. 2022 May 31;17(5):e0269260.
26. Perkowska-Ptasinska A, Bartczak A, Wagrowska-Danilewicz M, Halon A, Okon K, Wozniak A, Danilewicz M, Karkoszka H, Marszałek A, Kowalewska J, Mroz A. Clinicopathologic correlations of renal pathology in the adult population of Poland. Nephrology Dialysis Transplantation. 2017 Apr 1;32(suppl_2):ii209-18.
27. Arora P, Roychaudhury A, Pandey R. Non-diabetic renal diseases in patients with diabetes mellitus clinicopathological correlation. Indian Journal of Nephrology. 2020 Sep 1;30(5):295-300.
28. Muthukumar P, Dhanapriya J, Gopalakrishnan N, Dineshkumar T, Sakthirajan R, Balasubramaniyan T. Evaluation of renal lesions and clinicopathologic correlation in rheumatoid arthritis. Saudi journal of kidney diseases and transplantation. 2017 Jan 1;28(1):44-50.
29. Buckley LF, Schmidt IM, Verma A, Palsson R, Adam D, Shah AM, Srivastava A, Waikar SS. Associations between kidney histopathologic lesions and incident cardiovascular disease in adults with chronic kidney disease. JAMA cardiology. 2023 Apr 1;8(4):357-65.
30. Grenier N, Merville P, Combe C. Radiologic imaging of the renal parenchyma structure and function. Nature Reviews Nephrology. 2016 Jun;12(6):348-59.
31. Sinn DH, Kang D, Jang HR, Gu S, Cho SJ, Paik SW, Ryu S, Chang Y, Lazo M, Guallar E, Cho J. Development of chronic kidney disease in patients with non-alcoholic fatty liver disease: a cohort study. Journal of hepatology. 2017 Dec 1;67(6):1274-80.
32. Inoue T, Kozawa E, Ishikawa M, Fukaya D, Amano H, Watanabe Y, Tomori K, Kobayashi N, Niitsu M, Okada H. Comparison of multiparametric magnetic resonance imaging sequences with laboratory parameters for prognosticating renal function in chronic kidney disease. Scientific reports. 2021 Nov 11;11(1):22129.
33. Weinreb JC, Rodby RA, Yee J, Wang CL, Fine D, McDonald RJ, Perazella MA, Dillman JR, Davenport MS. Use of intravenous gadolinium-based contrast media in patients with kidney disease: consensus statements from the American College of Radiology and the National Kidney Foundation. Radiology. 2021 Jan;298(1):28-35.
34. Collister D, Ferguson T, Komenda P, Tangri N. The patterns, risk factors, and prediction of progression in chronic kidney disease: a narrative review. InSeminars in nephrology 2016 Jul 1 (Vol. 36, No. 4, pp. 273-282). WB Saunders.
35. Tangri N, Inker LA, Hiebert B, Wong J, Naimark D, Kent D, Levey AS. A dynamic predictive model for progression of CKD. American Journal of Kidney Diseases. 2017 Apr 1;69(4):514-20.
36. Ali I, Chinnadurai R, Ibrahim ST, Green D, Kalra PA. Predictive factors of rapid linear renal progression and mortality in patients with chronic kidney disease. BMC nephrology. 2020 Aug 14;21(1):345.
37. Radcliffe NJ, Seah JM, Clarke M, MacIsaac RJ, Jerums G, Ekinci EI. Clinical predictive factors in diabetic kidney disease progression. Journal of diabetes investigation. 2017 Jan;8(1):6-18.
38. Lim DK, Boyd JH, Thomas E, Chakera A, Tippaya S, Irish A, Manuel J, Betts K, Robinson S. Prediction models used in the progression of chronic kidney disease: A scoping review. PLoS One. 2022 Jul 26;17(7):e0271619.

39. Chang HL, Wu CC, Lee SP, Chen YK, Su W, Su SL. A predictive model for progression of CKD. Medicine. 2019 Jun 1;98(26):e16186.
40. Evans M, Lewis RD, Morgan AR, Whyte MB, Hanif W, Bain SC, Davies S, Dashora U, Yousef Z, Patel DC, Strain WD. A narrative review of chronic kidney disease in clinical practice: current challenges and future perspectives. Advances in therapy. 2022 Jan;39(1):33-43.
41. Hazzan AD, Halinski C, Agoritsas S, Fishbane S, DeVita MV. Epidemiology and challenges to the management of advanced CKD. Advances in chronic kidney disease. 2016 Jul 1;23(4):217-21.